The Committee to Restore Nymox Shareholder Value Issues Notice of Special Meeting of Nymox Pharmaceutical Shareholders
The Committee to Restore Nymox Shareholder Value, Inc. (CRNSV), with a goal to recover shareholder value in Nymox Pharmaceutical Corporation (NYMX-F) (the “Company” or “Nymox”), today announced that pursuant to the October 5, 2023 Order of Court in Bahamas Supreme Court (the “Court”) Action No. 2023/Com/com/00057 (the “Order”), it has issued notice of the special meeting of Nymox shareholders (the “Notice”) to be held at Margaritaville Beach Resort, 2 Bay St., Nassau, Bahamas, at 9 a.m. (EST) on November 8, 2023 (the “Special Meeting”). As set forth in the Notice, CRNSV is calling the Special Meeting for the purpose of approving proposals to significantly improve the Company’s leadership and governance, including proposals relating to the termination of Dr. Paul Averback as President and Chief Executive Officer of the Company and reconstitution of the Nymox Board of Directors (the “Board”) through the removal of each incumbent Board member and appointment of five highly qualified nominees as directors of the Company.
The Court ordered the Company to give notice of the convening of a shareholder meeting by October 9, 2023 to be held no later than 28 days from such notice and if Nymox fails to do so, the Order empowers CRNSV to give notice of the shareholder meeting itself. CRNSV is therefore providing Notice of the Special Meeting given the Company’s failure to do so within the requisite deadline provided in the Order. Importantly, the Order presents shareholders with a critical opportunity to right the ship at Nymox, but it is ultimately up to us, the shareholders, to take action and seize this vital opportunity at the upcoming Special Meeting. CRNSV looks forward to sharing further details regarding the Special Meeting and the proposals to be presented at such Special Meeting.
The full text of the Notice is provided below:
NYMOX PHARMACEUTICAL CORPORATION
(COMPANY NO. 175894B)
Pursuant to the International Business Companies Act, Ch. 309, Statute Laws of the Bahamas
NOTICE OF THE SPECIAL MEETING OF SHAREHOLDERS
CALLED BY THE COMMITTEE TO RESTORE NYMOX SHAREHOLDER VALUE
Consisting of the following individual participants:
Randall Lanham, Chris Riley, M. Richard Cutler
TO: Shareholders of Nymox Pharmaceutical Corporation (“Nymox” or the “Company”):
Notice is hereby given that pursuant to the October 5, 2023 Order of Court in Bahamas Supreme Court (the “Court”) Action No. 2023/Com/com/00057, a Special Meeting of the Shareholders of Nymox is being called by the Committee to Restore Nymox Shareholder Value, Inc. (“CRNSV”) to be held at Margaritaville Beach Resort, 2 Bay St., Nassau, Bahamas, at 9 a.m. (EST) on November 8, 2023 (the “Special Meeting”) for the purpose of approving proposals to significantly improve the Company’s leadership and governance, including proposals relating to the termination of Dr. Paul Averback as President and Chief Executive Officer of the Company and reconstitution of the Nymox Board of Directors (the “Board”) through the removal of each incumbent Board member and appointment of five highly-qualified nominees as directors of the Company.
CRNSV intends to provide further details regarding the Special Meeting and the proposals to be presented at such Special Meeting and will be disseminating relevant materials to shareholders in furtherance thereof.
All long-suffering Nymox shareholders, regardless of the size of their holdings, are invited to join the rapidly growing coalition by visiting the fully dedicated website https://crnsv.com/ reviewing all the relevant information and signing up for further updates, this will be a key communication platform as we move into the solicitation process. There is no obligation to join or support required and all personal contact information and identification will be confidential and protected. CRNSV will contact each shareholder to confirm participation and support for the changes called for in Nymox.
Thank you for your support,
/s/ Randall Lanham
Randall Lanham, on behalf of CRNSV
About The Committee to Restore Nymox Shareholder Value, Inc. (CRNSV)
CRNSV was formed by former executives of the NYMOX PHARMACEUTICAL CORP ("NYMX-F") with a goal to restore shareholder value in NYMOX (the Company). With a commitment to overcome the steep decline and volatility of the stock price following the catastrophic NASDAQ Delisting Decision, CRNSV has issued rebuttal letters to all Company shareholders and continues to emphasize lack of Company leadership, inability to realize the potential for valuable and promising results through a relationship with a highly respected global healthcare and specialty pharmacy solutions company with expertise to help commercialize the Company’s Benign Prostatic Hyperplasia (BPH) product, and Nymox’s lack of solution or plan for financial recovery of shareholder value. Headquartered in Carson City, Nevada with offices in London, CRNSV documents are available at https://www.crnsv.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MSCI Appoints Jana Haines as Head of Index30.11.2023 15:14:00 CET | Press release
MSCI Inc. (NYSE: MSCI), a leading provider of mission-critical decision support tools and services for the global investment community, today announced that Jana Haines has joined the firm as Head of Index and as a member of MSCI’s Executive Committee. Based in New York, Ms. Haines will be responsible for the strategic development and execution of MSCI’s global Index product line. She will partner with senior leaders across the firm to manage the Index product development process. Ms. Haines will aim to drive innovation across index categories, including market cap, sustainability, climate, factors, thematics and asset classes, such as fixed income and private assets. "As a longtime business leader, Jana has a proven track record of strategic thinking and a unique understanding of the value of MSCI’s indexes to investors,” said Baer Pettit, President and Chief Operating Officer of MSCI. “Jana’s extensive expertise in the global financial industry will be critical to MSCI building an ev
Empatica Announces Plans for Landmark Clinical Study to Develop an AI-Based Seizure Forecast Based on Wearable Real-World Data30.11.2023 14:29:00 CET | Press release
Empatica, a digital health and AI company developing medical-grade wearables and digital biomarkers for health monitoring and diagnostics, today announced plans to launch a first-of-its-kind study aimed at developing a seizure forecasting algorithm for people living with epilepsy, based on real-world data collected using its technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231130692933/en/ Empatica announces plans to develop an AI-based seizure forecasting algorithm based on wearable real-world Data (Graphic: Business Wire) More than 3 million Americans suffer from epilepsy, according to numbers from the Centers for Disease Control. And around one third of people with epilepsy have refractory epilepsy which occurs when medications no longer control seizures1. Epileptic seizures are disruptive health events that can have a significant negative impact on quality of life and increase risk of injury and death for peopl
QPS Holdings, LLC divests its Neuropharmacology Business Unit30.11.2023 14:15:00 CET | Press release
Today QPS Holdings, LLC (QPS) a leading drug development Contract Research Organization (CRO), announces an agreement to sell its Neuropharmacology business unit (QPS Neuropharmacology) to Scantox, a leading Nordic pre-clinical, GLP-accredited CRO. QPS Neuropharmacology, based in Grambach, Austria and focused on drug discovery, specializes in neurodegenerative diseases, rare diseases and mental disorders. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231130940694/en/ QPS Neuropharmacology facility in Grambach, Austria. (Graphic: Business Wire) Founded in 1999, QPS Neuropharmacology has built a strong global reputation for high quality services that are deeply scientifically rooted and has an undisputed track-record of serving a loyal and broad customer base globally. This long history of developing expertise within neuropharmacology preclinical studies has contributed to strong year-on-year growth and positioned the organiz
ASICS Teams Up with BlueConic for Enhanced Personalization and Data Privacy Compliance30.11.2023 13:00:00 CET | Press release
ASICS, the global leader in athletic footwear and apparel, has selected pure-play customer data platform (CDP) BlueConic to reimagine the way it engages with customers. The move will empower the ASICS team to support a growing number of personalization projects while remaining compliant with consumer data privacy regulations around the globe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231128796155/en/ ASICS teams up with BlueConic to deliver personalization at scale. (Photo: Business Wire) With operations across the Americas, Europe, the Middle East, Asia, and Oceania, ASICS is best known for its sports apparel, shoes, equipment, and accessories for men, women, and children. The company acquired fitness app RunKeeper in 2016 for its potential as a one-on-one marketing channel. With a focus on increasing engagement and loyalty both within the app and across brands, channels, and regions, ASICS will use BlueConic to unify
LTIMindtree Partners with Metasphere to Deliver Smart Sewers Solutions30.11.2023 12:00:00 CET | Press release
LTIMindtree [NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company, announced that it has been selected as a strategic partner by Metasphere, a wastewater application specialist, to scale their Smart Sewers management platform. As a part of this engagement, LTIMindtree will transform Metasphere’s next-generation wastewater monitoring solution portfolio, and enable scalable delivery and platform to their customers. Metasphere, part of Grundfos, provides smart network management solutions to the global utility industry. The company helps customers prevent leaks and spills for a cleaner, greener world and has deployed more than 200K sensors for their customers worldwide. By leveraging cutting-edge technology, the company offers intelligent, innovative, all-in-one wastewater application solutions. These solutions provide full network visibility, performance and forecasting that reduce telemetry ownership cost for customers to manage time-critical remote asse